Merck to discontinue bacterial infection drug Zinplava
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-12-26 12:14 GMT | Update On 2024-12-26 12:14 GMT
Merck will discontinue its antibody-drug Zinplava for a bacterial infection that can lead to fatal diarrhea, according to the U.S. Food and Drug Administration's website.
Zinplava, first approved by the regulator in 2016 for prevention of the recurrence of Clostridioides difficile infections (CDI), a bacterial infection often caused by prolonged use of antibiotics. CDI can lead to potentially fatal diarrhea and inflammation of the colon.
The FDA’s website states that the discontinuation of Zinplava will take effect on January 31, but no reason was cited for this decision.
The drugmaker did not immediately comment on the matter, Reuters reported.
Medical Dialogues team had earlier reported that the Company had announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. Vibostolimab was being evaluated as an investigational fixed-dose combination with pembrolizumab (KEYTRUDA ) in the KeyVibe program. Favezelimab was being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYFORM program.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.